Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Research

CircPVT1 promotes proliferation of lung squamous cell carcinoma by binding to miR-30d/e

Authors: Jie Shi, Xin Lv, Lizhong Zeng, Wei Li, Yujie Zhong, Jingyan Yuan, Shanshan Deng, Boxuan Liu, Bo Yuan, Yang Chen, Zongjuan Ming, Xia Yang, Ping Fang, Shuanying Yang, Guoan Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Circular RNAs (circRNAs) are a new type of extensive non-coding RNAs that regulate the activation and progression of different human diseases, including cancer. However, information on the underlying mechanisms and clinical significance of circRNAs in lung squamous cell carcinoma (LUSC) remains scant.

Methods

The expression profile of RNAs in 8 LUSC tissues, and 9 healthy lung tissues were assayed using RNA sequencing (RNA-seq) techniques. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to profile the expression of circPVT1 and its relationship with the prognosis of LUSC, i.e., survival analysis. Moreover, in vitro and in vivo experiments were performed to evaluate the impacts of circPVT1 on the growth of tumors. RNA pull-down tests, mass spectrometry, dual-luciferase reporter assessment, and RNA immune-precipitation tests were further conducted to interrogate the cross-talk between circPVT1, HuR, or miR-30d/e in LUSC.

Results

Our data showed that circPVT1 was upregulated in LUSC tissues, serum, and cell lines. LUSC patients with higher circPVT1 expression exhibited shorter survival rates. The in vivo and in vitro data revealed that circPVT1 promotes the proliferation of LUSC cells. Additionally, mechanistic analysis showed that HuR regulated circPVT1. On the other hand, circPVT1 acted as a competing endogenous RNA (ceRNA) of miR-30d and miR-30e in alleviating the suppressive influences of miR-30d and miR-30e on its target cyclin F (CCNF).

Conclusion

CircPVT1 promotes LUSC progression via HuR/circPVT1/miR-30d and miR-30e/CCNF cascade. Also, it acts as a novel diagnostic biomarker or treatment target of individuals diagnosed with LUSC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46. https://doi.org/10.1038/nrc3775.CrossRefPubMedPubMedCentral

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57. https://doi.org/10.1261/rna.035667.112.CrossRefPubMedPubMedCentral

Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant RNAs. Int J Mol Sci. 2014;15(6):9331–42. https://doi.org/10.3390/ijms15069331.CrossRefPubMedPubMedCentral

Su X, Wang H, Ge W, Yang M, Hou J, Chen T, et al. An in vivo method to identify microRNA targets not predicted by computation algorithms: p21 targeting by miR-92a in Cancer. Cancer Res. 2015;75(14):2875–85. https://doi.org/10.1158/0008-5472.CAN-14-2218.CrossRefPubMed

Zhuang H, Wu F, Wei W, Dang Y, Yang B, Ma X, et al. Glycine decarboxylase induces autophagy and is downregulated by miRNA-30d-5p in hepatocellular carcinoma. Cell Death Dis. 2019;10(3):192. https://doi.org/10.1038/s41419-019-1446-z.CrossRefPubMedPubMedCentral

Zhuang L, Shou T, Li K, Gao CL, Duan LC, Fang LZ, et al. MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma. J Cell Mol Med. 2017;21(11):2852–62. https://doi.org/10.1111/jcmm.13198.CrossRefPubMedPubMedCentral

Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–42. https://doi.org/10.1016/j.molcel.2018.06.034.CrossRefPubMed

10.

Ju HQ, Zhao Q, Wang F, et al. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. Embo Mol Med. 2019;11:e10168.CrossRefPubMedPubMedCentral

11.

Tang W, Fu K, Sun H, Rong D, Wang H, Cao H. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018;17(1):137. https://doi.org/10.1186/s12943-018-0888-8.CrossRefPubMedPubMedCentral

12.

Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer. 2019;18(1):4. https://doi.org/10.1186/s12943-018-0933-7.CrossRefPubMedPubMedCentral

13.

Liang WC, Wong CW, Liang PP, Shi M, Cao Y, Rao ST, et al. Translation of the circular RNA circbeta-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20(1):84. https://doi.org/10.1186/s13059-019-1685-4.CrossRefPubMedPubMedCentral

14.

Hanna N, Johnson D, Temin S, Masters G. Systemic therapy for stage IV non-small-cell lung Cancer: American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract. 2017;13(12):832–7. https://doi.org/10.1200/JOP.2017.026716.CrossRefPubMed

15.

The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25. https://doi.org/10.1038/nature11404.

16.

Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, et al. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017;36(10):1384–93. https://doi.org/10.1038/onc.2016.303.CrossRefPubMed

17.

Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 2017;388:208–19. https://doi.org/10.1016/j.canlet.2016.12.006.CrossRefPubMed

18.

Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Vitale J, Colombo T, et al. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol. 2017;18(1):237. https://doi.org/10.1186/s13059-017-1368-y.CrossRefPubMedPubMedCentral

19.

Panda AC, Grammatikakis I, Kim KM, de S, Martindale JL, Munk R, et al. Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res. 2017;45(7):4021–35. https://doi.org/10.1093/nar/gkw1201.CrossRefPubMed

20.

Li X, Zhang Z, Jiang H, Li Q, Wang R, Pan H, et al. Circular RNA circPVT1 promotes proliferation and invasion through sponging miR-125b and activating E2F2 signaling in non-small cell lung Cancer. Cell Physiol Biochem. 2018;51(5):2324–40. https://doi.org/10.1159/000495876.CrossRefPubMed

21.

Qin S, Zhao Y, Lim G, Lin H, Zhang X, Zhang X. Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. Biomed Pharmacother. 2019;111:244–50. https://doi.org/10.1016/j.biopha.2018.12.007.CrossRefPubMed

22.

Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. 2019;18(1):158. https://doi.org/10.1186/s12943-019-1094-z.CrossRefPubMedPubMedCentral

23.

Li XX, Xiao L, Chung HK, Ma XX, Liu X, Song JL, et al. circPABPN1 Interaction between HuR and Modulates Autophagy in the Intestinal Epithelium by Altering ATG16L1 Translation. Mol Cell Biol. 2020;40(6):e00492–19. https://doi.org/10.1128/MCB.00492-19.

24.

Lan Y, Xiao X, He Z, Luo Y, Wu C, Li L, et al. Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res. 2018;46(11):5809–21. https://doi.org/10.1093/nar/gky214.CrossRefPubMedPubMedCentral

25.

Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, de S, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–9. https://doi.org/10.1080/15476286.2017.1279788.CrossRefPubMedPubMedCentral

26.

Ye Z, Li J, Han X, Hou H, Chen H, Zheng X, et al. TET3 inhibits TGF-beta1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells. J Exp Clin Cancer Res. 2016;35(1):72. https://doi.org/10.1186/s13046-016-0350-y.CrossRefPubMedPubMedCentral

27.

Lin ZY, Chen G, Zhang YQ, He HC, Liang YX, Ye JH, et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16(1):48. https://doi.org/10.1186/s12943-017-0615-x.CrossRefPubMedPubMedCentral

28.

Zheng M, Hou L, Ma Y, Zhou L, Wang F, Cheng B, et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019;18(1):76. https://doi.org/10.1186/s12943-019-0999-x.CrossRefPubMedPubMedCentral

29.

Bjornetro T, Redalen KR, Meltzer S, et al. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019;8(1):1567219. https://doi.org/10.1080/20013078.2019.1567219.CrossRefPubMedPubMedCentral

30.

Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013;81(3):388–96. https://doi.org/10.1016/j.lungcan.2013.05.007.CrossRefPubMed

31.

Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang L, et al. MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 2015;362(2):208–17. https://doi.org/10.1016/j.canlet.2015.03.041.CrossRefPubMed

32.

Wu Y, Zhang J, Hou S, Cheng Z, Yuan M. Non-small cell lung cancer: miR-30d suppresses tumor invasion and migration by directly targeting NFIB. Biotechnol Lett. 2017;39(12):1827–34. https://doi.org/10.1007/s10529-017-2428-9.CrossRefPubMed

33.

Deng L, Tang J, Yang H, Cheng C, Lu S, Jiang R, et al. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway. Oncogene. 2017;36(28):3976–85. https://doi.org/10.1038/onc.2016.491.CrossRefPubMed

34.

Croset M, Pantano F, Kan C, et al. miRNA-30 family members inhibit breast Cancer invasion, Osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 2018;78(18):5259–73. https://doi.org/10.1158/0008-5472.CAN-17-3058.CrossRefPubMed

35.

Cui Y, Zhao L, Zhao S, Guo T, Li F, Li Z, et al. MicroRNA-30e inhibits proliferation and invasion of non-small cell lung cancer via targeting SOX9. Hum Cell. 2019;32(3):326–33. https://doi.org/10.1007/s13577-018-0223-0.CrossRefPubMed

36.

Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R, et al. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res. 2018;362(2):268–78. https://doi.org/10.1016/j.yexcr.2017.11.027.CrossRefPubMed

37.

D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149(5):1023–34. https://doi.org/10.1016/j.cell.2012.03.043.CrossRefPubMedPubMedCentral

38.

Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404(6773):42–9. https://doi.org/10.1038/35003506.CrossRefPubMed

39.

Murray MJ, Saini HK, Siegler CA, Hanning JE, Barker EM, van Dongen S, et al. LIN28 expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Res. 2013;73(15):4872–84. https://doi.org/10.1158/0008-5472.CAN-12-2085.CrossRefPubMedPubMedCentral

40.

Hatfield KJ, Reikvam H, Bruserud O. Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert Opin Ther Targets. 2014;18(11):1237–51. https://doi.org/10.1517/14728222.2014.957671.CrossRefPubMed

Title: CircPVT1 promotes proliferation of lung squamous cell carcinoma by binding to miR-30d/e
Authors: Jie Shi
Xin Lv
Lizhong Zeng
Wei Li
Yujie Zhong
Jingyan Yuan
Shanshan Deng
Boxuan Liu
Bo Yuan
Yang Chen
Zongjuan Ming
Xia Yang
Ping Fang
Shuanying Yang
Guoan Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01976-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Forkhead box (FOX) G1 promotes hepatocellular carcinoma epithelial-Mesenchymal transition by activating Wnt signal through forming T-cell factor-4/Betacatenin/FOXG1 complex

Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer

circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling

RETRACTED ARTICLE: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

Gut microbiota influence tumor development and Alter interactions with the human immune system

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer